GLP-1 Drugs and Epilepsy: Do They Affect Seizure Risk? First Large-Scale Analysis
First study examining seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy, addressing a critical safety gap for the growing number of epilepsy patients taking these drugs.
Quick Facts
What This Study Found
First study examining seizure recurrence after GLP-1 RA initiation in epilepsy patients, providing initial safety data for this growing patient overlap.
Key Numbers
Study covered January 2003 to August 2025. Patients required 3+ epilepsy diagnoses for inclusion. Multiple GLP-1 drugs were studied: exenatide, liraglutide, dulaglutide, lixisenatide, and others.
How They Did This
Retrospective analysis of seizure recurrence patterns in adults with epilepsy who initiated GLP-1 receptor agonist therapy. Compared pre- and post-GLP-1 seizure rates.
Why This Research Matters
Epilepsy and metabolic disease commonly co-occur. Without safety data, clinicians were prescribing GLP-1 drugs to epilepsy patients blindly. This study provides the first evidence base for informed prescribing.
The Bigger Picture
As GLP-1 drugs are prescribed to broader populations, understanding their effects in patients with neurological conditions becomes critical. GLP-1 receptors are expressed throughout the brain, and their activation could theoretically affect seizure threshold in either direction.
What This Study Doesn't Tell Us
Retrospective design. Multiple confounders including weight changes, medication interactions, and variable seizure monitoring. Specific findings need prospective confirmation.
Questions This Raises
- ?Do GLP-1 drugs have pro- or anti-seizure effects through brain GLP-1 receptors?
- ?Should specific GLP-1 drugs be preferred or avoided in epilepsy patients?
- ?Do weight loss and metabolic improvement independently affect seizure control?
Trust & Context
- Key Stat:
- First epilepsy safety data Initial analysis of seizure recurrence after GLP-1 drug initiation in adults with epilepsy — filling a critical safety gap
- Evidence Grade:
- Preliminary evidence: first retrospective analysis of an unstudied patient population. Prospective studies needed.
- Study Age:
- Published in 2025. Addresses a previously unstudied safety question.
- Original Title:
- Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.
- Published In:
- Epilepsia (2025)
- Authors:
- AbuAlrob, Majd A(2), Hussein, Abdullah, Abdellatif, Rand, Itbaisha, Adham, Zammar, Khaled, Mesraoua, Boulenouar
- Database ID:
- RPEP-09756
Evidence Hierarchy
Frequently Asked Questions
Can I take GLP-1 drugs if I have epilepsy?
This first study specifically examined this question. While full results are in the paper, the fact that this analysis was conducted at all reflects growing recognition that many epilepsy patients need GLP-1 drugs. Discuss with both your neurologist and endocrinologist.
Could GLP-1 drugs affect seizures?
GLP-1 receptors exist in the brain, so GLP-1 drugs theoretically could affect seizure threshold. This study provides the first data on what actually happens to seizure patterns when epilepsy patients start GLP-1 drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09756APA
AbuAlrob, Majd A; Hussein, Abdullah; Abdellatif, Rand; Itbaisha, Adham; Zammar, Khaled; Mesraoua, Boulenouar. (2025). Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.. Epilepsia. https://doi.org/10.1111/epi.70022
MLA
AbuAlrob, Majd A, et al. "Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.." Epilepsia, 2025. https://doi.org/10.1111/epi.70022
RethinkPeptides
RethinkPeptides Research Database. "Seizure recurrence after GLP-1 receptor agonist initiation i..." RPEP-09756. Retrieved from https://rethinkpeptides.com/research/abualrob-2025-seizure-recurrence-after-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.